Innate Pharma SA
OTC:IPHYF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innate Pharma SA
OTC:IPHYF
|
FR |
|
L
|
Longino & Cardenal SpA
MIL:LON
|
IT |
|
National Grid PLC
LSE:NG
|
UK |
|
China Three Gorges Renewables Group Co Ltd
SSE:600905
|
CN |
|
C
|
China Securities Co Ltd
SWB:CS0
|
CN |
|
Flughafen Zuerich AG
F:UZAA
|
CH |
|
I
|
Innate Pharma SA
XBER:IDD
|
FR |
Wall St Price Targets
IPHYF Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPHYF is 5.56 USD with a low forecast of 4.63 USD and a high forecast of 6.63 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPHYF's stock price target?
Price Target
5.56
USD
According to Wall Street analysts, the average 1-year price target for IPHYF is 5.56 USD with a low forecast of 4.63 USD and a high forecast of 6.63 USD.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
